XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

Geneos Therapeutics, Inc. (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Noncontrolling Interest [Abstract] |
Schedule of Equity Method Investments | The following table shows the amounts related to the deconsolidation accounting:
Working capital (excluding cash) | $ | (59,992) |
Note payable | 171,620 |
Fixed assets, net of accumulated depreciation | (16,340) |
Carrying value of noncontrolling interest | 3,181,640 |
Fair value of investment in Geneos retained | 3,618,998 |
Gain on deconsolidation of Geneos | (4,121,075) |
Decrease in cash resulting from the deconsolidation of Geneos | $ | 2,774,851 |
The details of the Company’s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.
Geneos Share Class | Shares |  | Price per Share |  | Fair Value
Common | 3,000,000 |  |  | $ | 0.273 |  |  | $ | 819,000 |
Preferred | 2,113,206 |  |  | $ | 1.325 |  |  | $ | 2,799,998 |
Total | 5,113,206 |  |  |  |  | $ | 3,618,998 |
The remaining $1.8 million loss has been allocated to the Company’s preferred stock investment in Geneos, thereby reducing the balance to $958,000 as of September 30, 2020 as shown in the table below:
Investment in Geneos upon deconsolidation |  | $ | 3,618,998 |
Share in net loss of Geneos |  | $ | (2,661,431) |
Investment in Geneos as of September 30, 2020 |  | $ | 957,567 |
Schedule of Fair Value Measurement Inputs and Valuation Techniques | The assumptions used in the fair value calculation as of June 1, 2020 are presented below:
Expected term (years) | 2.92
Volatility | 70%
Risk-free interest rate | 2.46%
Geneos enterprise value | $4,966,531

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_NoncontrollingInterestAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration